August 13, 2012 — Royal Philips Electronics and Celsion Corp. announced that the U.S. Food and Drug Administration (FDA) has provided clearance to initiate a clinical study supporting a joint development program for Celsion’s ThermoDox combined with Philips' Sonalleve MR-HIFU (magnetic resonance-guided high intensity focused ultrasound) technology for the palliation of painful metastases to the bone caused by lung, prostate or breast cancers.